<DOC>
	<DOCNO>NCT02033889</DOCNO>
	<brief_summary>This efficacy safety study ertugliflozin participant type 2 diabetes mellitus inadequate glycemic control metformin monotherapy . The primary study hypothesis Week 26 , mean reduction baseline hemoglobin A1c ( HbA1c ) ertugliflozin great placebo .</brief_summary>
	<brief_title>A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy ( MK-8835-007 ) .</brief_title>
	<detailed_description>The trial include 13-15 week run-in period prior randomization , 26-week , double-blind , placebo-controlled treatment period ( Phase A ) follow 78-week double-blind , extension period ( Phase B ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Diagnosis T2DM accordance American Diabetes Association guideline Participants must receive metformin monotherapy less 8 week prior study participation require change diabetes regimen remain eligible participate trial ( include discontinue antihyperglycemic agent [ AHA ] therapy ) must hemoglobin A1c 7.0 10.5 % ( 5391 mmol/mol ) least 8 week regimen metformin monotherapy History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study participation A clinically significant electrocardiogram abnormality A history malignancy â‰¤5 year prior study participation , except adequately treat basal squamous cell skin cancer situ cervical cancer A know hypersensitivity intolerance sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor glimepiride On blood pressure lipid alter medication stable dose least 4 week prior study participation A surgical procedure within 6 week prior study participation plan major surgery trial Donation blood blood product within 6 week study participation plan donate blood blood product time trial Pregnant breastfeeding , expect conceive trial , include 14 day follow last dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>